Patent awarded to Cartherics for boosting immune cell performance in China
In a significant development, the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom has announced that QV Bioelectronics has been awarded £1.26M to advance studies on a new brain cancer treatment. The exact nature of the treatment being researched by QV Bioelectronics remains undisclosed.
Meanwhile, Cartherics, an Australian biotechnology company, has been granted a patent by the Chinese Patent Office for a 'Method for Providing Immune Cells with Enhanced Function'. This patent covers induced pluripotent stem cells (iPSCs) with a specific gene knock out of the adenosine A2A receptor (A2AR). The A2AR receptor is critical for inhibiting immune cell function in the tumor microenvironment of solid tumors, including brain cancer.
Prof. Alan Trounson AO, CEO of Cartherics, stated that blocking the A2AR gene is likely to be a significant addition to Cartherics' strategic arsenal against cancer. Removing the A2A receptor from Cartherics' NK cells should help these cells remain active in the tumor microenvironment, potentially improving the effectiveness of immunotherapies.
The patent strengthens Cartherics' already robust IP position, securing a proprietary position for multiple development candidates in their pipeline. Cartherics is focusing on developing off-the-shelf immunotherapies for high-impact women's diseases, including ovarian cancer, triple negative breast cancer, and endometriosis.
Elsewhere, AbbVie has received marketing authorisation from the MHRA for an unspecified product or treatment. The focus of the article in "Femtech News" is on female-focused technology in healthcare, or "Femtech". The article discusses the repurposing of technology in the medical field, with the title "MedTech: Repurposing is here to stay".
China's patent protection system offers substantial commercial value for effective patents. The patent secures a proprietary position for Cartherics' innovative approach to cancer treatment, potentially opening up new avenues for the development of effective therapies. The funding for QV Bioelectronics comes from an unspecified source, but the investment is a clear vote of confidence in their research and development efforts.
As the battle against cancer continues, advances like these offer hope for patients and their families. The research being conducted by QV Bioelectronics and Cartherics could lead to breakthroughs in the treatment of brain cancer and other solid tumors, potentially improving outcomes for those affected by these devastating diseases.
Read also:
- Understanding Hemorrhagic Gastroenteritis: Key Facts
- Stopping Osteoporosis Treatment: Timeline Considerations
- Tobacco industry's suggested changes on a legislative modification are disregarded by health journalists
- Expanded Community Health Involvement by CK Birla Hospitals, Jaipur, Maintained Through Consistent Outreach Programs Across Rajasthan
